Abstract
Metoprolol, a selective β1-adrenoreceptor blocking agent used in the treatment of hypertension, angina, and heart failure, is primarily metabolized by the CYP2D6 enzyme, which catalyzes α-hydroxylation and O-desmethylation. As CYP2D6 is genetically highly polymorphic and the enzymatic activity differs greatly depending on the presence of the mutant allele(s), the pharmacokinetic profile of metoprolol is highly variable depending on the genotype of CYP2D6. The aim of study was to develop the physiologically based pharmacokinetic (PBPK) model of metoprolol related to CYP2D6 genetic polymorphism for personalized therapy with metoprolol. For PBPK modelling, our previous pharmacogenomic data were used. To obtain kinetic parameters (Km, Vmax, and CLint) of each genotype, the recombinant CYP enzyme of each genotype was incubated with metoprolol and metabolic rates were assayed. Based on these data, the PBPK model of metoprolol was developed and validated in different CYP2D6 genotypes using PK-Sim® software. As a result, the input values for various parameters for the PBPK model were presented and the PBPK model successfully described the pharmacokinetics of metoprolol in each genotype group. The simulated values were within the acceptance criterion (99.998% confidence intervals) compared with observed values. The PBPK model developed in this study can be used for personalized pharmacotherapy with metoprolol in individuals of various races, ages, and CYP2D6 genotypes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abduljalil K, Badhan RKS (2020) Drug dosing during pregnancy-opportunities for physiologically based pharmacokinetic models. J Pharmacokinet Pharmacodyn 47(4):319–340. https://doi.org/10.1007/s10928-020-09698-w
Abduljalil K, Cain T, Humphries H, Rostami-Hodjegan A (2014) Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations. Drug Metab Dispos 42(9):1478–1484. https://doi.org/10.1124/dmd.114.058099
Bae SH, Lee JK, Cho DY, Bae SK (2014) Simultaneous determination of metoprolol and its metabolites, alpha-hydroxymetoprolol and O-desmethylmetoprolol, in human plasma by liquid chromatography with tandem mass spectrometry: application to the pharmacokinetics of metoprolol associated with CYP2D6 genotypes. J Sep Sci 37(11):1256–1264. https://doi.org/10.1002/jssc.201301353
Bae JW, Oh KY, Yoon SJ, Shin HB, Jung EH, Cho CK, Lim CW, Kang P, Choi CI, Jang CG, Lee SY, Lee YJ (2020) Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide. Arch Pharm Res 43(11):1207–1213. https://doi.org/10.1007/s12272-020-01293-4
Berezhkovskiy LM (2004) Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci 93(6):1628–1640. https://doi.org/10.1002/jps.20073
Bijl MJ, Visser LE, van Schaik RH, Kors JA, Witteman JC, Hofman A, Vulto AG, van Gelder T, Stricker BH (2009) Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin Pharmacol Ther 85(1):45–50. https://doi.org/10.1038/clpt.2008.172
Byeon JY, Kim YH, Na HS, Jang JH, Kim SH, Lee YJ, Bae JW, Kim IS, Jang CG, Chung MW, Lee SY (2015) Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites. Arch Pharm Res 38(11):2083–2091. https://doi.org/10.1007/s12272-015-0646-z
Byeon JY, Kim YH, Lee CM, Kim SH, Chae WK, Jung EH, Choi CI, Jang CG, Lee SY, Bae JW, Lee YJ (2018a) CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes. Arch Pharm Res 41(19):921–930. https://doi.org/10.1007/s12272-018-1075-6
Byeon JY, Lee YJ, Kim YH, Kim SH, Lee CM, Bae JW, Jang CG, Lee SY, Choi CI (2018b) Effects of diltiazem, a moderate inhibitor of CYP3A4, on the pharmacokinetics of tamsulosin in different CYP2D6 genotypes. Arch Pharm Res 41(5):564–570. https://doi.org/10.1007/s12272-018-1030-6
Byeon JY, Lee CM, Lee YJ, Kim YH, Kim SH, Jung EH, Chae WK, Lee YJ, Jang CG, Lee SY (2019) Influence of CYP2D6 genetic polymorphism on pharmacokinetics of active moiety of tolterodine. Arch Pharm Res 42(2):182–190. https://doi.org/10.1007/s12272-018-1099-y
Cerqueira PM, Coelho EB, Geleilete TJ, Goldman GH, Lanchote VL (2005) Influence of chronic renal failure on stereoselective metoprolol metabolism in hypertensive patients. J Clin Pharmacol 45(12):1422–1433. https://doi.org/10.1177/0091270005281816
Chen Y, ** JY, Mukadam S, Malhi V, Kenny JR (2012) Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies. Biopharm Drug Dispos 33(2):85–98. https://doi.org/10.1002/bdd.1769
Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY (2021a) Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele. Arch Pharm Res 44(11):1037–1049. https://doi.org/10.1007/s12272-021-01357-z
Cho CK, Park HJ, Kang P, Moon S, Lee YJ, Bae JW, Jang CG, Lee SY (2021b) Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes. Arch Pharm Res 44(12):1076–1090. https://doi.org/10.1007/s12272-021-01361-3
Choi CI, Bae JW, Jang CG, Lee SY (2012) Tamsulosin exposure is significantly increased by the CYP2D6*10/*10 genotype. J Clin Pharmacol 52(12):1934–1938. https://doi.org/10.1177/0091270011432168
Coppola P, Kerwash E, Cole S (2021) Physiologically based pharmacokinetics model in pregnancy: a regulatory perspective on model evaluation. Front Pediatr 9:687978. https://doi.org/10.3389/fped.2021.687978
Drugs.com (2021) Metoprolol. https://www.drugs.com/metoprolol.html. Accessed 10 April 2022
Eddington ND, Rekhi GS, Lesko LJ, Augsburger LL (2000) Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations. AAPS PharmSciTech 1(2):E14. https://doi.org/10.1208/pt010214
Eichelbaum M, Ingelman-Sundberg M, Evans WE (2006) Pharmacogenomics and individualized drug therapy. Annu Rev Med 57:119–137. https://doi.org/10.1146/annurev.med.56.082103.104724
Guo J, Zhou D, Li Y, Khanh BH (2015) Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors. Biopharm Drug Dispos 36(8):507–519. https://doi.org/10.1002/bdd.1962
Hansch C, Hoekman D, Leo A, Zhang L, Li P (1995) The expanding role of quantitative structure-activity relationships (QSAR) in toxicology. Toxicol Lett 79(1–3):45–53. https://doi.org/10.1016/0378-4274(95)03356-p
Heimbach T, Chen Y, Chen J, Dixit V, Parrott N, Peters SA, Poggesi I, Sharma P, Snoeys J, Shebley M, Tai G, Tse S, Upreti VV, Wang YH, Tsai A, **a B, Zheng M, Zhu AZX, Hall S (2021) Physiologically-based pharmacokinetic modeling in renal and hepatic impairment populations: a pharmaceutical industry perspective. Clin Pharmacol Ther 110(2):297–310. https://doi.org/10.1002/cpt.2125
Huang J, Chuang SK, Cheng CL, Lai ML (1999) Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes. Clin Pharmacol Ther 65(4):402–407. https://doi.org/10.1016/S0009-9236(99)70134-7
** SK, Chung HJ, Chung MW, Kim JI, Kang JH, Woo SW, Bang S, Lee SH, Lee HJ, Roh J (2008) Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. J Clin Pharm Ther 33(5):567–573. https://doi.org/10.1111/j.1365-2710.2008.00945.x
Jung EH, Lee CM, Byeon JY, Shin HB, Oh KY, Cho CK, Lim CW, Jang CG, Lee SY, Lee YJ (2020a) Relationship between plasma exposure of zolpidem and CYP2D6 genotype in healthy Korean subjects. Arch Pharm Res 43(9):976–981. https://doi.org/10.1007/s12272-020-01250-1
Jung EH, Lee YJ, Kim DH, Kang P, Lim CW, Cho CK, Jang CG, Lee SY, Bae JW (2020b) Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes. Arch Pharm Res 43(12):1356–1363. https://doi.org/10.1007/s12272-020-01300-8
Jung EH, Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Choi CI, Jang CG, Lee SY (2021) Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients. Arch Pharm Res 44(12):1109–1119. https://doi.org/10.1007/s12272-021-01363-1
Kim SH, Byeon JY, Kim YH, Lee CM, Lee YJ, Jang CG, Lee SY (2018) Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes. Sci Rep 8(1):12405. https://doi.org/10.1038/s41598-018-30841-8
Kim YH, Kang P, Cho CK, Jung EH, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY (2021) Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism. Arch Pharm Res 44(7):713–724. https://doi.org/10.1007/s12272-021-01346-2
Kim NT, Cho CK, Kang P, Park H-J, Lee YJ, Bae JW, Jang C-G, Lee S-Y (2022) Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects. Arch Pharm Res 45(2):114–121. https://doi.org/10.1007/s12272-021-01366-y
Kirchheiner J, Tsahuridu M, Jabrane W, Roots I, Brockmöller J (2004) The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations. Per Med 1(1):63–84. https://doi.org/10.1517/17410541.1.1.63
Krauwinkel W, Dickinson J, Schaddelee M, Meijer J, Tretter R, van de Wetering J, Strabach G, van Gelderen M (2014) The effect of mirabegron, a potent and selective beta3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. Eur J Drug Metab Pharmacokinet 39(1):43–52. https://doi.org/10.1007/s13318-013-0133-1
Lee CM, Jung EH, Byeon JY, Kim SH, Jang CG, Lee YJ, Lee SY (2019) Effects of steady-state clarithromycin on the pharmacokinetics of zolpidem in healthy subjects. Arch Pharm Res 42(12):1101–1106. https://doi.org/10.1007/s12272-019-01201-5
Li X, Frechen S, Moj D, Lehr T, Taubert M, Hsin C-h, Mikus G, Neuvonen PJ, Olkkola KT, Saari TI, Fuhr U (2020) A physiologically based pharmacokinetic model of voriconazole integrating time-dependent inhibition of CYP3A4, genetic polymorphisms of CYP2C19 and predictions of drug–drug Interactions. Clin Pharmacokinet 59(6):781–808. https://doi.org/10.1007/s40262-019-00856-z
McFarland JW, Avdeef A, Berger CM, Raevsky OA (2001) Estimating the water solubilities of crystalline compounds from their chemical structures alone. J Chem Inf Comput Sci 41(5):1355–1359. https://doi.org/10.1021/ci0102822
Park MH, Shin SH, Byeon JJ, Lee GH, Yu BY, Shin YG (2017) Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: a case study of caffeine and ciprofloxacin. Korean J Physiol Pharmacol 21(1):107–115. https://doi.org/10.4196/kjpp.2017.21.1.107
Poulin P, Theil FP (2000) A priori prediction of tissue: plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 89(1):16–35. https://doi.org/10.1002/(SICI)1520-6017(200001)89:1<16::AIDJPS3>3.0.CO;2-E
Poulin P, Theil FP (2002a) Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 91(1):129–156. https://doi.org/10.1002/jps.10005
Poulin P, Schoenlein K, Theil FP (2001) Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. J Pharm Sci 90(4):436–447. https://doi.org/10.1002/1520-6017(200104)90:4<436::aid-jps1002>3.0.co;2-p
Poulin P, Theil FP (2002b) Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 91(5):1358–1370. https://doi.org/10.1002/jps.10128
Rasool MF, Khalil F, Läer S (2017) Optimizing the clinical use of carvedilol in liver cirrhosis using a physiologically based pharmacokinetic modeling approach. Eur J Drug Metab Pharmacokinet 42(3):383–396. https://doi.org/10.1007/s13318-016-0353-2
Regårdh CG, Ablad B, Borg KO, Johnsson G, Solvell L (1974) Proceedings: Relationship between the pharmacokinetic and pharmacodynamic properties of the beta-receptor antagonists alprenolol and metoprolol. Acta Pharm Suec 11(6):660
Regårdh CG, Jordö L, Ervik M, Lundborg P, Olsson R, Rönn O (1981) Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. Clin Pharmacokinet 6(5):375–388. https://doi.org/10.2165/00003088-198106050-00004
Rodgers T, Rowland M (2006) Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95(6):1238–1257. https://doi.org/10.1002/jps.20502
Rodgers T, Rowland M (2007) Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res 24(5):918–933. https://doi.org/10.1007/s11095-006-9210-3
Rodgers T, Leahy D, Rowland M (2005a) Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94(6):1259–1276. https://doi.org/10.1002/jps.20322
Rodgers T, Leahy D, Rowland M (2005b) Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat. J Pharm Sci 94(6):1237–1248. https://doi.org/10.1002/jps.20323
Schmitt W (2008) General approach for the calculation of tissue to plasma partition coefficients. Toxicol In Vitro 22(2):457–467. https://doi.org/10.1016/j.tiv.2007.09.010
Sharma A, Pibarot P, Pilote S, Dumesnil JG, Arsenault M, Bélanger PM, Meibohm B, Hamelin BA (2005) Modulation of metoprolol pharmacokinetics and hemodynamics by diphenhydramine coadministration during exercise testing in healthy premenopausal women. J Pharmacol Exp Ther 313(3):1172–1181. https://doi.org/10.1124/jpet.104.081109
Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270(1):414–423
Shin HB, Jung EH, Kang P, Lim CW, Oh KY, Cho CK, Lee YJ, Choi CI, Jang CG, Lee SY, Bae JW (2020) ABCB1 c.2677G > T/c.3435 C > T diplotype increases the early-phase oral absorption of losartan. Arch Pharm Res 43(11):1187–1196. https://doi.org/10.1007/s12272-020-01294-3
Suri A, Chapel S, Lu C, Venkatakrishnan K (2015) Physiologically based and population PK modeling in optimizing drug development: a predict–learn–confirm analysis. Clin Pharmacol Ther 98(3):336–344. https://doi.org/10.1002/cpt.155
Thelen K, Coboeken K, Willmann S, Burghaus R, Dressman JB, Lippert J (2011) Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions. J Pharm Sci 100(12):5324–5345. https://doi.org/10.1002/jps.22726
Verscheijden LFM, Koenderink JB, Johnson TN, de Wildt SN, Russel FGM (2020) Physiologically-based pharmacokinetic models for children: starting to reach maturation? Pharmacol Ther 211:107541. https://doi.org/10.1016/j.pharmthera.2020
Wang Y, Zhou L, Dutreix C, Leroy E, Yin Q, Sethuraman V, Riviere GJ, Yin OQ, Schran H, Shen ZX (2008) Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. Br J Clin Pharmacol 65(6):885–892. https://doi.org/10.1111/j.1365-2125.2008.03150.x
Wojtyniak JG, Selzer D, Schwab M, Lehr T (2021) Physiologically based precision dosing approach for drug–drug‐gene interactions: a simvastatin network analysis. Clin Pharmacol Ther 109(1):201–211. https://doi.org/10.1002/cpt.2111
Wuttke H, Rau T, Heide R, Bergmann K, Böhm M, Weil J, Werner D, Eschenhagen T (2002) Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 72(4):429–437. https://doi.org/10.1067/mcp.2002.127111
Xu M, Zheng L, Zeng J, Xu W, Jiang X, Wang L (2021) Physiologically based pharmacokinetic modeling of tramadol to inform dose adjustment and drug–drug interactions according to CYP2D6 phenotypes. Pharmacotherapy 41(3):277–290. https://doi.org/10.1002/phar.2494
Yellepeddi V, Rower J, Liu X, Kumar S, Rashid J, Sherwin CMT (2019) State-of-the-art review on physiologically based pharmacokinetic modeling in pediatric drug development. Clin Pharmacokinet 58(1):1–13. https://doi.org/10.1007/s40262-018-0677-y
Zhuang X, Lu C (2016) PBPK modeling and simulation in drug research and development. Acta Pharm Sin B 6(5):430–440. https://doi.org/10.1016/j.apsb.2016.04.004
Acknowledgements
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT, and Future Planning (Grant No. NRF-2019R1A2C1004582).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Lee, CM., Kang, P., Cho, C. et al. Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes. Arch. Pharm. Res. 45, 433–445 (2022). https://doi.org/10.1007/s12272-022-01394-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-022-01394-2